Codexis (CDXS) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Codexis (CDXS) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 44.9% versus a loss of 47.8%. Over five years, VYGR leads with a -39.8% price change compared with -95.0% for CDXS. Codexis is the larger company by market cap ($154.4 million vs $152.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDXS | VYGR |
|---|---|---|
| Share price | $1.41 | $2.47 |
| Market cap | $154.40M | $152.20M |
| 1-day change | +3.68% | +0.41% |
| YTD return | -13.50% | -37.15% |
| 1-year return | -44.92% | -47.78% |
| 5-year return | -95.02% | -39.76% |
| EPS (TTM) | $-0.33 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.98 | $5.55 |
| 52-week low | $0.96 | $2.39 |
| Distance from 52-week high | -52.68% | -55.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +335.46% | +502.83% |
| Average volume | 1.10M | 563.34K |
| Shares outstanding | 109.51M | 61.62M |
| Employees | 146 | 141 |
| Sector | Industrials | Health Care |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Codexis in Industrials and Voyager Therapeutics in Health Care.
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
CDXS vs VYGR FAQ
Which is bigger, Codexis or Voyager Therapeutics?
Codexis (CDXS) is larger, with a market capitalization of $154.40M compared with $152.20M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, CDXS or VYGR?
CDXS returned -44.92% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Codexis and Voyager Therapeutics in the same industry?
No. Codexis is in the Industrials sector, while Voyager Therapeutics is in Health Care.